

Metformin inhibits disease progression in non-diabetic chronic kidney disease

April 14 2021




Figure 1. *Scientific Reports* (2021). DOI: 10.1038/s41598-021-86109-1

Researchers from Kumamoto University (Japan) have found that the anti-

diabetic drug metformin significantly prolongs the survival of mice in a model that simulates the pathology of non-diabetic chronic kidney disease (ND-CKD) by ameliorating pathological conditions like reduced kidney function, glomerular damage, inflammation and fibrosis.

Metformin's mechanism is different from existing therapeutics which only treat symptoms, such as the blood pressure drug losartan, so the researchers believe that a combination of these medications at low dose will be highly beneficial.

CKD ([chronic kidney disease](#)) is a general term for [kidney damage](#) that results from persistent decline in [kidney](#) function due to proteinuria, kidney inflammation, or fibrosis. As CKD progresses, patients are forced to undergo dialysis, and diabetes is one of its biggest risk factors. CKD can also occur in association with lifestyle-related conditions such as hypertension, insufficient exercise, smoking, hyperuricemia, and mutations in kidney-related genes. This type of CKD is classified as non-diabetic chronic kidney disease (ND-CKD) and has limited treatment options.

Alport syndrome is an inherited kidney disease that falls under the ND-CKD umbrella. In Alport syndrome, abnormalities in type 4 collagen, a constituent of the membrane responsible for urine filtration in the kidney, cause abnormal glomerular filtration which results in chronic loss of kidney function. It is a serious disease that eventually progresses to end-stage renal failure, requiring dialysis or kidney transplant. As with diabetic kidney disease and ND-CKD, Alport syndrome is currently treated by maintaining kidney function using [blood pressure](#)-lowering drugs but patients eventually transition to end-stage [renal failure](#). Therefore, a new therapeutic agent that is effective and safe enough to be administered to patients for a long period of time is needed.

Metformin is used as a treatment for type 2 diabetes because it improves insulin sensitivity. It is an inexpensive and safe drug that has been used

by diabetics for many years. Interestingly, because of its mechanism of action, metformin was also known to be protective against many diseases involving inflammation and fibrosis, and was known to improve the renal pathology of diabetic kidney disease. However, it was unclear whether metformin also had a protective effect on ND-CKD, which is not caused by diabetes.

Researchers selected an Alport syndrome mouse model for their ND-CKD experiments and worked to identify novel therapeutic targets based on pathogenic mechanisms. They focused on drugs traditionally used for CKD patients, metformin and [losartan](#)—which works by lowering blood pressure and inhibiting proteinuria caused by increased glomerular filtration.

Administration of metformin or losartan to ND-CKD model mice significantly suppressed proteinuria and serum creatinine, which are indicators of CKD. Inflammation and fibrosis, which also reduce [kidney function](#), significantly improved. Furthermore, metformin was found to have a nephroprotective effect similar to losartan.

The results of a detailed gene expression analysis found that the renal pathology of the ND-CKD mouse model was caused by abnormal expression of genes related to glomerular epithelial cell podocytes (cells responsible for kidney filtering) and genes involved in intracellular metabolism. Interestingly, the improvement caused by losartan was limited to genes involved in podocyte abnormalities. Metformin, on the other hand, improved the expression of genes related to podocyte abnormalities and those related to intracellular metabolism. In other words, metformin clearly has a different target of action (also improved targeting of metabolic abnormalities) from that of losartan.

Finally, they found that administration of low-dose metformin and losartan to model mice significantly prolonged their survival.

Researchers also found that in studies using doses at which metformin alone was not effective, the combination of metformin and losartan significantly prolonged mice survival. Put plainly, this study showed that an appropriate combination of the two therapeutic drugs could effectively treat the ND-CKD (Alport syndrome) mouse model.

This study raises the possibility that metformin, a proven and inexpensive diabetic drug, may delay the progression of kidney pathology in ND-CKD, including Alport syndrome. Metformin is currently available for use in patients with diabetes in clinical practice, but not in non-diabetic patients.

"This study appears to show that metformin has therapeutic effects for both diabetic and non-diabetic kidney disease," said Professor Hirofumi Kai, who led the research project. "However, metformin is contraindicated in patients with severe renal dysfunction (eGFR

This research found that the appropriate combination of metformin and losartan significantly improved renal pathology and prolonged survival in a ND-CKD mouse model. This suggests that the old inexpensive drug [metformin](#) could become a new inexpensive [drug](#) for patients with chronic kidney [disease](#).

More information: Kohei Omachi et al. Metformin ameliorates the severity of experimental Alport syndrome, *Scientific Reports* (2021). [DOI: 10.1038/s41598-021-86109-1](https://doi.org/10.1038/s41598-021-86109-1)

Provided by Kumamoto University

Citation: Metformin inhibits disease progression in non-diabetic chronic kidney disease (2021, April 14) retrieved 26 April 2024 from <https://medicalxpress.com/news/2021-04-metformin->

[inhibits-disease-non-diabetic-chronic.html](#)

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.